Abstract #3221

Clinical viable QSM using accelerated, segmented 3D EPI with inline, automated QSM post-processing

Monique Tourell^1,2, Ashley Stewart^1,2, Jin Jin^2,3,4,5, Sunil Patil⁶, Kieran O'Brien^1,2,3, Simon Robinson^1,7,8, and Markus Barth^1,2,5

¹Centre for Advanced Imaging, University of Queensland, Brisbane, Australia, ²ARC Training Centre for Innovation in Biomedical Imaging Technology, The University of Queensland, Brisbane, Australia, ³Siemens Healthcare Pty Ltd, Brisbane, Australia, ⁴Mark and Mary Stevens Neuroimaging and Informatics Institute, University of Southern California, Los Angeles, CA, United States, ⁵School of Information Technology and Electrical Engineering, the University of Queensland, Brisbane, Australia, ⁶Siemens Healthcare Pty Ltd, Malvern, PA, United States, ⁷High Field Magnetic Resonance Centre, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria, ⁸Department of Neurology, Medical University of Graz, Graz, Austria

Successful translation of QSM into the clinic requires the combination of fast imaging protocols with robust, automated on-scanner processing. In this work we present clinical viable QSM: acquisition of phase data using accelerated, segmented 3D EPI in 30 seconds, and automated QSM post-processing on the scanner in under 2 minutes. The resultant susceptibility maps were of comparable quality to those obtained using a GRE sequence. Analysis of the susceptibilities measured within the caudate, putamen and pallidum demonstrates that 3D EPI with on-scanner processing produces susceptibility values in good agreement with those obtained from a GRE sequence, and offline processing pipelines.

This abstract and the presentation materials are available to members only; a login is required.

Join Here